- Research works
- 84 ▲ 271% vs 2018-21
- Citations
- 2.9k 34.9 per fractional work
- Top-10% rate
- 14.8% all institutions 10.0%
- Open access
- 48% world 40%
- International
- 27% world 18%
Not ranked overall: NewGen Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does NewGen Therapeutics (United States) work in?
In 2022-now, 59% of research at NewGen Therapeutics (United States) is in Health Sciences, 39% in Life Sciences. Its largest fields are Medicine (58%), Biochemistry, Genetics and Molecular Biology (33%), Immunology and Microbiology (5%). It does 2.2× the world's share of Life Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 14 fields, with their numbers
- Health Sciences2058.9%
- Medicine2058.5%
- Veterinary00.3%
- Health Professions00.1%
- Life Sciences1339.1%
- Physical Sciences11.8%
- Chemistry00.8%
- Engineering00.4%
- Materials Science00.2%
- Energy00.1%
- Environmental Science00.1%
- Social Sciences00.3%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.1×. Every wedge is a field page.
All 14 fields, with their numbers
- Biochemistry, Genetics and Molecular Biology6.11×11 works
- Immunology and Microbiology4.67×2 works
- Medicine3.04×20 works
- Veterinary2.40×0 works
- Neuroscience0.85×0 works
- Chemistry0.53×0 works
- Energy0.15×0 works
- Agricultural and Biological Sciences0.09×0 works
- Materials Science0.06×0 works
- Economics, Econometrics and Finance0.06×0 works
- Health Professions0.04×0 works
- Business, Management and Accounting0.04×0 works
- Engineering0.03×0 works
- Environmental Science0.03×0 works
- Biochemistry, Genetics and Molecular Biology 6.1×
- Immunology and Microbiology 4.7×
- Medicine 3.0×
- Veterinary 2.4×
- Neuroscience 0.8×
- Chemistry 0.5×
- Energy 0.1×
- Agricultural and Biological Sciences 0.1×
- Materials Science 0.1×
- Economics, Econometrics and Finance 0.1×
- Health Professions 0.0×
- Business, Management and Accounting 0.0×
- Engineering 0.0×
- Environmental Science 0.0×
Which keywords describe research at NewGen Therapeutics (United States)?
By fractional works in 2022-now, weighted toward what it does more of than the world: Treatment, Diagnosis, Immunotherapy, Epidemiology, Cancer Immunotherapy, Tumor Regression, Antibiotic Resistance and CAR T Cells.
- Genomic Integration
- Toll-like Receptors
- Cell Signaling
- Tuberculosis
- Inflammation
- Breast Cancer
- Vaccine
- Gene Therapy
- Chemotherapy
- Cancer
- Mycobacterium avium
- CAR T Cells
- Tumor Regression
- Immunotherapy
- Diagnosis
- Epidemiology
- Treatment
- Cancer Immunotherapy
- Antibiotic Resistance
- Chimeric Antigen Receptor
- Nontuberculous Mycobacteria
- Immune Response
- Cancer Therapy
- Drug Resistance
- Angiogenesis
- Genetic Diversity
- Mycobacterium tuberculosis
- Innate Immunity
- Targeted Therapy
- Tumor Microenvironment
- Glycosylation
Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 31 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 31 words, with their numbers
- Epidemiology5▲ 3.6×11 topics
- Diagnosis4▲ 14×5 topics
- Treatment4▲ 10×6 topics
- Immunotherapy4▲ 15×9 topics
- Cancer Immunotherapy3▲ 59×3 topics
- Tumor Regression3▲ 70×2 topics
- Antibiotic Resistance2▲ 18×2 topics
- CAR T Cells2▲ 93×1 topic
- Chimeric Antigen Receptor2▲ 93×1 topic
- Mycobacterium avium2▲ 208×1 topic
- Nontuberculous Mycobacteria2▲ 208×1 topic
- Cancer2▲ 4.6×12 topics
- Immune Response2▲ 11×8 topics
- Chemotherapy2▲ 8.5×7 topics
- Cancer Therapy2▲ 9.9×8 topics
- Gene Therapy2▲ 29×5 topics
- Drug Resistance2▲ 18×3 topics
- Vaccine2▲ 12×4 topics
- Angiogenesis2▲ 14×4 topics
- Breast Cancer2▲ 19×4 topics
- Genetic Diversity2▲ 10×2 topics
- Inflammation2▲ 2.2×9 topics
- Mycobacterium tuberculosis2▲ 79×1 topic
- Tuberculosis2▲ 83×1 topic
- Innate Immunity1▲ 12×4 topics
- Cell Signaling1▲ 25×3 topics
- Targeted Therapy1▲ 18×4 topics
- Toll-like Receptors1▲ 30×3 topics
- Tumor Microenvironment1▲ 7.6×4 topics
- Genomic Integration1▲ 57×2 topics
- Glycosylation1▲ 29×2 topics
Which research topics does NewGen Therapeutics (United States) publish most on?
By volume in 2022-now: CAR-T cell therapy research, Mycobacterium research and diagnosis, Tuberculosis Research and Epidemiology and CRISPR and Genetic Engineering.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 2 works
- 2 Mycobacterium research and diagnosis Epidemiology 2 works
- 3 Tuberculosis Research and Epidemiology Infectious Diseases 2 works
- 4 CRISPR and Genetic Engineering Molecular Biology 1 works
- 5 Virus-based gene therapy research Genetics 1 works
- 6 Proteoglycans and glycosaminoglycans research Cell Biology 1 works
- 7 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 8 Colorectal Cancer Treatments and Studies Oncology 1 works
- 9 Immunotherapy and Immune Responses Immunology 1 works
- 10 Cancer Immunotherapy and Biomarkers Oncology 1 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has NewGen Therapeutics (United States)'s research output changed?
Output in 2022-2025 was 271% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is NewGen Therapeutics (United States) as a percentage of every work published that year, 0.00012% in 2024.
Fractional works of NewGen Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Menlo Park
- SRI International
- Meta (United States)
- Exponent (United States)
- Pacific Biosciences (United States)
- ATUM (United States)
- Personalis (United States)
- Geron (United States)
- Alpha Omega Alpha Medical Honor Society
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about NewGen Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.